$6.83
Revenue is up for the last 2 quarters, 14.44M → 16.54M (in $), with an average increase of 12.7% per quarter
Netprofit is up for the last 2 quarters, -52.42M → -45.85M (in $), with an average increase of 14.3% per quarter
In the last 1 year, Seagen Inc has given 44.0% return, outperforming this stock by 65.6%
In the last 3 years, Moderna Inc has given 21.0% return, outperforming this stock by 100.2%
2.34%
Downside
Day's Volatility :9.99%
Upside
7.83%
15.67%
Downside
52 Weeks Volatility :57.33%
Upside
49.41%
Period | Alector Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -17.11% | 0.7% | -7.0% |
6 Months | -24.95% | -7.9% | -6.5% |
1 Year | -21.58% | -2.0% | -6.8% |
3 Years | -79.24% | 25.4% | 24.7% |
Market Capitalization | 620.1M |
Book Value | $2.2 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.62 |
Wall Street Target Price | 11.0 |
Profit Margin | -107.05% |
Operating Margin TTM | -114.43% |
Return On Assets TTM | -10.56% |
Return On Equity TTM | -59.73% |
Revenue TTM | 125.7M |
Revenue Per Share TTM | 1.52 |
Quarterly Revenue Growth YOY | -32.4% |
Gross Profit TTM | -76.8M |
EBITDA | -138.3M |
Diluted Eps TTM | -1.62 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.06 |
EPS Estimate Next Year | -2.42 |
EPS Estimate Current Quarter | -0.75 |
EPS Estimate Next Quarter | -0.82 |
What analysts predicted
Upside of 61.05%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 3.7M | ↑ 797.84% |
Net Income | -32.5M | ↑ 114.96% |
Net Profit Margin | -869.61% | ↑ 2762.6% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 27.7M | ↑ 641.02% |
Net Income | -52.2M | ↑ 60.86% |
Net Profit Margin | -188.78% | ↑ 680.83% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 21.2M | ↓ 23.33% |
Net Income | -105.4M | ↑ 101.7% |
Net Profit Margin | -496.65% | ↓ 307.87% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 21.1M | ↓ 0.57% |
Net Income | -190.2M | ↑ 80.51% |
Net Profit Margin | -901.64% | ↓ 404.99% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 207.1M | ↑ 881.54% |
Net Income | -36.3M | ↓ 80.9% |
Net Profit Margin | -17.54% | ↑ 884.1% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 133.6M | ↓ 35.48% |
Net Income | -133.3M | ↑ 266.95% |
Net Profit Margin | -99.77% | ↓ 82.23% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 14.0M | ↓ 92.33% |
Net Income | -55.6M | ↓ 143.93% |
Net Profit Margin | -397.37% | ↓ 466.77% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 24.5M | ↑ 74.89% |
Net Income | -44.6M | ↓ 19.77% |
Net Profit Margin | -182.3% | ↑ 215.07% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 79.9M | ↑ 226.27% |
Net Income | 9.9M | ↓ 122.15% |
Net Profit Margin | 12.38% | ↑ 194.68% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 14.9M | ↓ 81.4% |
Net Income | -46.1M | ↓ 566.94% |
Net Profit Margin | -310.72% | ↓ 323.1% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 14.4M | ↓ 2.77% |
Net Income | -52.4M | ↑ 13.61% |
Net Profit Margin | -363.07% | ↓ 52.35% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.5M | ↑ 14.61% |
Net Income | -45.9M | ↓ 12.53% |
Net Profit Margin | -277.1% | ↑ 85.97% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 236.1M | ↑ 336.25% |
Total Liabilities | 288.1M | ↑ 264.59% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 308.4M | ↑ 30.63% |
Total Liabilities | 405.8M | ↑ 40.84% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 421.9M | ↑ 36.83% |
Total Liabilities | 227.2M | ↓ 44.01% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 488.3M | ↑ 15.72% |
Total Liabilities | 220.7M | ↓ 2.84% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 814.7M | ↑ 66.85% |
Total Liabilities | 513.9M | ↑ 132.84% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 787.6M | ↓ 3.32% |
Total Liabilities | 573.2M | ↑ 11.53% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 814.7M | ↓ 4.63% |
Total Liabilities | 513.9M | ↓ 0.85% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 954.5M | ↑ 17.16% |
Total Liabilities | 686.9M | ↑ 33.66% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 889.7M | ↓ 6.79% |
Total Liabilities | 601.2M | ↓ 12.49% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 837.0M | ↓ 5.92% |
Total Liabilities | 583.9M | ↓ 2.86% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 787.6M | ↓ 5.9% |
Total Liabilities | 573.2M | ↓ 1.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 748.3M | ↓ 4.99% |
Total Liabilities | 565.3M | ↓ 1.37% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.8M | ↑ 36.77% |
Investing Cash Flow | -801.0K | ↓ 64.4% |
Financing Cash Flow | -15.0K | ↓ 80.52% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 127.5M | ↓ 817.26% |
Investing Cash Flow | -224.1M | ↑ 27879.9% |
Financing Cash Flow | 131.1M | ↓ 874406.67% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -99.3M | ↓ 177.91% |
Investing Cash Flow | -48.9M | ↓ 78.19% |
Financing Cash Flow | 172.4M | ↑ 31.42% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -166.7M | ↑ 67.9% |
Investing Cash Flow | -105.1M | ↑ 114.94% |
Financing Cash Flow | 232.1M | ↑ 34.67% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 298.6M | ↓ 279.06% |
Investing Cash Flow | -49.7M | ↓ 52.72% |
Financing Cash Flow | 30.3M | ↓ 86.95% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -49.3M | ↓ 111.07% |
Investing Cash Flow | -146.8M | ↑ 112.52% |
Financing Cash Flow | 8.6M | ↓ 41.72% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 135.1M | ↓ 374.21% |
Investing Cash Flow | -12.1M | ↓ 91.75% |
Financing Cash Flow | 2.5M | ↓ 71.25% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -57.4M | ↓ 142.52% |
Investing Cash Flow | -225.8M | ↑ 1765.35% |
Financing Cash Flow | 906.0K | ↓ 63.51% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -49.1M | ↓ 14.6% |
Investing Cash Flow | 60.5M | ↓ 126.8% |
Financing Cash Flow | 489.0K | ↓ 46.03% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -48.5M | ↓ 0.77% |
Investing Cash Flow | 88.7M | - |
Financing Cash Flow | 1.1M | ↑ 69.65% |
Sell
Neutral
Buy
Alector Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Alector Inc | 6.89% | -24.95% | -21.58% | -79.24% | -62.06% |
![]() Moderna, Inc. | -2.19% | -29.52% | -8.32% | 114.67% | 590.97% |
![]() Regeneron Pharmaceuticals, Inc. | -8.43% | -4.6% | 15.93% | 18.38% | 134.28% |
![]() Seagen, Inc. | -2.63% | 59.03% | 43.99% | 21.05% | 216.49% |
![]() Vertex Pharmaceuticals Incorporated | -6.48% | 0.7% | 19.84% | 13.84% | 116.25% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Alector Inc | 15.47 | NA | NA | -3.06 | -0.6 | -0.11 | 0.0 | 2.2 |
![]() Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.91 | 19.91 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.18 | 26.18 | 0.41 | 14.61 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Alector Inc | Buy | $620.1M | -62.06% | 15.47 | -107.05% |
![]() Moderna, Inc. | Buy | $49.1B | 590.97% | 11.46 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $80.7B | 134.28% | 19.91 | 33.81% |
![]() Seagen, Inc. | Hold | $36.7B | 216.49% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $83.3B | 116.25% | 26.18 | 35.4% |
BlackRock Inc
Vanguard Group Inc
FMR Inc
Federated Hermes Inc
EcoR1 Capital, LLC
State Street Corporation
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain's immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company's immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer's disease. This scientific approach is also the basis for the Company's immuno-oncology programs.
Organization | Alector Inc |
Employees | 273 |
CEO | Dr. Tillman Ulf Gerngross Ph.D. |
Industry | Biotechnology |
PowerShares SP MidCap Low Volatility ETF
$49.79
+0.48%
SPDR NYSE Technology ETF
$131.78
+1.16%
ProShares UltraPro Dow30 ETF
$53.74
+1.15%
Teucrim Soybean Fund
$24.43
+1.52%
CRESCENT CAPITAL BDC INC
$13.63
+1.11%
Fusion Pharmaceuticals Inc
$5.02
-1.57%
AMC Networks Inc.
$11.41
+0.88%
EVGO INC CL A
$4.01
+1.26%
CONNECT BIOPHARMA HOLDINGS L
$1.11
+2.42%